Nissan -Model LIVALO -Pitavastatin Calcium
This is an antihypercholesterolemic agent characteristic of having a strong LDL cholesterol reduction effect and causing less drug-interactions. It is recognized as one of the “Strong statins” in clinical practice. In Japan, it is distributed by Kowa Company, Limited. It has been launched in 30 countries, such as the United States and countries in Latin America, Europe and Asia. It is also under the process of launching in other countries as well as the development of compound drugs.
Furthermore, Nissan Chemical discovered a new drug, pitavastatin calcium (brand name: LIVALO®*), which has a strong LDL cholesterol reduction effect and launched by Kowa Company, Limited in 2003 on the Japanese market. Currently, it is sold in 30 countries around the world and is also under the process of launching in other countries and territories, as well as the development of compound drugs.
Concerning the new drug development pipeline, a pharmacological treatment for arrhythmia (NTC-801) is under the process of development. The former R&D section for pharmaceuticals was integrated to the Planning and Development Division from April 2022, making the Healthcare Division to handle manufacturing and sales of new drugs, medical materials, etc. From here on, the Healthcare Division will be committed to healthcare business from a broader, holistic viewpoint, not just focusing on pharmaceuticals but also medical materials.
- Pitavastatin calcium
(brand name: LIVALO®) - This is an antihypercholesterolemic agent characteristic of having a strong LDL cholesterol reduction effect and causing less drug-interactions. It is recognized as one of the “Strong statins” in clinical practice. In Japan, it is distributed by Kowa Company, Limited. It has been launched in 30 countries, such as the United States and countries in Latin America, Europe and Asia. It is also under the process of launching in other countries as well as the development of compound drugs.
- Efonidipine hydrochloride
(brand name: LANDEL®, FINTE®) - This is a long-acting calcium channel blocker characteristic of having renal protective functions. It is used for treating hypertension and angina. It is distributed by Zeria Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd. in Japan, and by GC Biopharma Corp. in South Korea.
- NTC-801 (pharmacological treatment for arrhythmia)
- It is a therapeutic agent which selectively inhibits acetylcholine-sensitive muscarinic potassium channels (KACh) and may be administered orally. KACh is known to be expressed only in the atrium, not in the ventricle. Since it will not interfere with the functions of the ventricles, NTC-801 has the potential to be a flawless treatment option for arrhythmia.